Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Evaluation of 451 Danish Boys with Delayed Puberty: Diagnostic use of a new Puberty Nomogram and Effects of Oral Testosterone Therapy

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{5fbcb96a5a8849518a2cb2a9db477c7c,
title = "Evaluation of 451 Danish Boys with Delayed Puberty: Diagnostic use of a new Puberty Nomogram and Effects of Oral Testosterone Therapy",
abstract = "Context: Few data exist on the diagnostic criteria, and on the effects of puberty induction, in boys with constitutional delay in growth and puberty (CDGP). Objective: To develop puberty nomograms based on Danish boys with normal pubertal development. To evaluate the different diagnostic criteria and the effect of oral testosterone undecanoate (TU) in boys with CDGP. Design: A cross-sectional and longitudinal study of Danish boys with normal pubertal development (COPENHAGEN puberty study). A retrospective observational study of 451 boys evaluated for delayed puberty between 1990 and 2013. Setting: Tertiary referral centre for pediatric endocrinology. Participants: One hundred and sixty-four (36{\%}) boys evaluated for CDGP were excluded due to missing data, reclassification, or associated comorbidities, yielding 287 (64{\%}) eligible for analysis. Main Outcome Measures: The number of patients with CDGP classified by the puberty nomogram (genital stage < -2 SD for age) versus the classical criteria (genital stage 1 at ≥ 14 years). The effect of one year of oral TU treatment on pubertal progression, circulating hormones, height, and predicted adult height (PAH). Results: Seventy-eight (27{\%}) of the 287 boys had delayed pubertal onset according to the classical criteria, whereas 173 (60{\%}) of the 287 boys had impaired pubertal progression according to the puberty nomogram. Ninety-six (56{\%}) of these 173 boys were treated with oral TU for 0.8 years (0.5;1.3) [median (25th;75th percentiles)], which resulted in beneficial effects on pubertal progression. Height increased from -1.9 SD (-2.5;-1.2) to -1.5 SD (-2.1;0.7) (p<0.001), and PAH increased from 172.3 cm (170.3;182.8) to 178.1 cm (171.4;191.7) (p=0.001) following one year of treatment. Conclusions: The puberty nomogram evaluates both delayed pubertal onset as well as delayed pubertal progression and allows separation of normal versus abnormal pubertal development. Oral TU treatment was followed by pubertal induction and progression and short-term growth without compromising final height.",
author = "Lawaetz, {Jacob Gerner} and Hagen, {Casper P} and {Grunnet Mieritz}, Mikkel and {Blomberg Jensen}, Martin and {Holm Petersen}, J{\o}rgen and Anders Juul",
year = "2015",
month = "1",
day = "16",
doi = "10.1210/jc.2014-3631",
language = "English",
volume = "100",
pages = "1376--85",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The/Endocrine Society",
number = "4",

}

RIS

TY - JOUR

T1 - Evaluation of 451 Danish Boys with Delayed Puberty

T2 - Diagnostic use of a new Puberty Nomogram and Effects of Oral Testosterone Therapy

AU - Lawaetz, Jacob Gerner

AU - Hagen, Casper P

AU - Grunnet Mieritz, Mikkel

AU - Blomberg Jensen, Martin

AU - Holm Petersen, Jørgen

AU - Juul, Anders

PY - 2015/1/16

Y1 - 2015/1/16

N2 - Context: Few data exist on the diagnostic criteria, and on the effects of puberty induction, in boys with constitutional delay in growth and puberty (CDGP). Objective: To develop puberty nomograms based on Danish boys with normal pubertal development. To evaluate the different diagnostic criteria and the effect of oral testosterone undecanoate (TU) in boys with CDGP. Design: A cross-sectional and longitudinal study of Danish boys with normal pubertal development (COPENHAGEN puberty study). A retrospective observational study of 451 boys evaluated for delayed puberty between 1990 and 2013. Setting: Tertiary referral centre for pediatric endocrinology. Participants: One hundred and sixty-four (36%) boys evaluated for CDGP were excluded due to missing data, reclassification, or associated comorbidities, yielding 287 (64%) eligible for analysis. Main Outcome Measures: The number of patients with CDGP classified by the puberty nomogram (genital stage < -2 SD for age) versus the classical criteria (genital stage 1 at ≥ 14 years). The effect of one year of oral TU treatment on pubertal progression, circulating hormones, height, and predicted adult height (PAH). Results: Seventy-eight (27%) of the 287 boys had delayed pubertal onset according to the classical criteria, whereas 173 (60%) of the 287 boys had impaired pubertal progression according to the puberty nomogram. Ninety-six (56%) of these 173 boys were treated with oral TU for 0.8 years (0.5;1.3) [median (25th;75th percentiles)], which resulted in beneficial effects on pubertal progression. Height increased from -1.9 SD (-2.5;-1.2) to -1.5 SD (-2.1;0.7) (p<0.001), and PAH increased from 172.3 cm (170.3;182.8) to 178.1 cm (171.4;191.7) (p=0.001) following one year of treatment. Conclusions: The puberty nomogram evaluates both delayed pubertal onset as well as delayed pubertal progression and allows separation of normal versus abnormal pubertal development. Oral TU treatment was followed by pubertal induction and progression and short-term growth without compromising final height.

AB - Context: Few data exist on the diagnostic criteria, and on the effects of puberty induction, in boys with constitutional delay in growth and puberty (CDGP). Objective: To develop puberty nomograms based on Danish boys with normal pubertal development. To evaluate the different diagnostic criteria and the effect of oral testosterone undecanoate (TU) in boys with CDGP. Design: A cross-sectional and longitudinal study of Danish boys with normal pubertal development (COPENHAGEN puberty study). A retrospective observational study of 451 boys evaluated for delayed puberty between 1990 and 2013. Setting: Tertiary referral centre for pediatric endocrinology. Participants: One hundred and sixty-four (36%) boys evaluated for CDGP were excluded due to missing data, reclassification, or associated comorbidities, yielding 287 (64%) eligible for analysis. Main Outcome Measures: The number of patients with CDGP classified by the puberty nomogram (genital stage < -2 SD for age) versus the classical criteria (genital stage 1 at ≥ 14 years). The effect of one year of oral TU treatment on pubertal progression, circulating hormones, height, and predicted adult height (PAH). Results: Seventy-eight (27%) of the 287 boys had delayed pubertal onset according to the classical criteria, whereas 173 (60%) of the 287 boys had impaired pubertal progression according to the puberty nomogram. Ninety-six (56%) of these 173 boys were treated with oral TU for 0.8 years (0.5;1.3) [median (25th;75th percentiles)], which resulted in beneficial effects on pubertal progression. Height increased from -1.9 SD (-2.5;-1.2) to -1.5 SD (-2.1;0.7) (p<0.001), and PAH increased from 172.3 cm (170.3;182.8) to 178.1 cm (171.4;191.7) (p=0.001) following one year of treatment. Conclusions: The puberty nomogram evaluates both delayed pubertal onset as well as delayed pubertal progression and allows separation of normal versus abnormal pubertal development. Oral TU treatment was followed by pubertal induction and progression and short-term growth without compromising final height.

U2 - 10.1210/jc.2014-3631

DO - 10.1210/jc.2014-3631

M3 - Journal article

VL - 100

SP - 1376

EP - 1385

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -

ID: 44860144